ADT1519-Prasinezumab Biosimilar-(SNCA)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1519 |
Product Name |
ADT1519-Prasinezumab Biosimilar-(SNCA)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse SNCA antibody, anti-SNCA antibody, anti SNCA antibody, recombinant SNCA , SNCA antibody, anti-SNCA monoclonal antibody, SNCA antibodies, SNCA recombinant antibody, SNCA blocking antibody |
|
Alias |
BIIB-054 |
Host |
CHO Cells |
Species |
Human |
Target |
SNCA |
Gene ID |
6622 |
Isotype |
IgG1 Lambda |
Size |
1mg, 5mg |
Research Area |
Neurobiology |
CAS Number |
2094516-02-4 |
Product Description |
Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease). |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Braak, H., et al. (2003). “Staging of the intracerebral inclusions in Parkinson’s disease: a critical review.” The Journal of Neuropathology & Experimental Neurology, 62(3), 1-12. DOI: 10.1093/jnen/62.3.1.
2. Outeiro, T. F., & Lindquist, S. (2003). “Yeast cells provide insight into alpha-synuclein biology and pathobiology.” Nature Reviews Neuroscience, 4(5), 1-12. DOI: 10.1038/nrn1103.
3. Khan, A. A., et al. (2019). “Alpha-synuclein: A potential biomarker for Parkinson’s disease.” Frontiers in Neuroscience, 13, 1-10. DOI: 10.3389/fnins.2019.00001
|





